search
Back to results

High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma

Primary Purpose

Parathyroid Adenomas

Status
Terminated
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
High Intensity Focused Ultrasound
Sponsored by
Oxford University Hospitals NHS Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parathyroid Adenomas focused on measuring Primary Parathyroid Adenomas

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Primary Hyperparathyroidism (PHPT)
  • Moderate/severe hypercalcaemia (Ca>2.8mmol/L)
  • Positive sestamibi scan demonstrating a cervical parathyroid adenoma
  • Adenoma visible on ultrasound scan

Exclusion Criteria:

  • Large adenoma (>15mm)
  • Deep adenoma (>20mm from skin surface
  • Familial disease (eg members of MEN-1 families)
  • Inability to complete questionnaires in English without making mistakes or needing help with translation

Sites / Locations

  • John Radcliffe Hospital

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

HIFU Treatment

Arm Description

High Intensity Focused Ultrasound. This is not a comparative study

Outcomes

Primary Outcome Measures

Eucalcaemia
Calcium in the blood is measured from venepuncture

Secondary Outcome Measures

Eucalcaemia
Ca in plasma
Voice Morbidity
Voice Handicap Index. 30 questions rated on a five point scale from 'never' to 'always' and an overall score from 1 'normal' to 10 'severely impaired'

Full Information

First Posted
February 7, 2011
Last Updated
November 7, 2017
Sponsor
Oxford University Hospitals NHS Trust
Collaborators
Theraclion
search

1. Study Identification

Unique Protocol Identification Number
NCT01291498
Brief Title
High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma
Official Title
High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma
Study Type
Interventional

2. Study Status

Record Verification Date
July 2014
Overall Recruitment Status
Terminated
Why Stopped
The manufacturer is not currently supporting research in this indication.
Study Start Date
April 2011 (undefined)
Primary Completion Date
June 2013 (Actual)
Study Completion Date
June 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Oxford University Hospitals NHS Trust
Collaborators
Theraclion

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aims to determine whether HIFU treatment is a safe and effective alternative to an operation to remove all or part of the affected gland. The objective is to achieve biochemical cure (assessed by normal calcium level in the blood at six weeks, six months and one year after therapy) without affecting the patient's voice or ability to swallow.
Detailed Description
Primary hyperparathyroidism is a common endocrine condition in which one or more of the four parathyroid glands in the neck releases too much parathyroid hormone (PTH). this leads to excess calcium in the blood and if untreated it can cause osteoporosis, kidney stone formation, deterioration of kidney function and disturbance in heart rhythm. Surgery to remove all or part of the affected gland(s) is expected to cure 95% of such patients. In current practice all such patients undergo localisation techniques using sestamibi scanning and neck ultrasonography to demonstrate the position of the enlarged/overactive parathyroid gland. These radiological tests are positive in some two thirds of patients, who can be operated through a minimally invasive procedure focused on the exact localisation pinpointed by the scans. This study uses a procedure that does not require a surgical incision. Precise imaging of the parathyroid glands allows the exact position of the tumour to be found from outside the body. A High Intensity Focused Ultrasound beam produces heat, but only in a small specific area. Exact positioning of the ultrasound beam targets the tumour cells and kills them without harming the surrounding healthy tissues.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parathyroid Adenomas
Keywords
Primary Parathyroid Adenomas

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
1 (Actual)

8. Arms, Groups, and Interventions

Arm Title
HIFU Treatment
Arm Type
Other
Arm Description
High Intensity Focused Ultrasound. This is not a comparative study
Intervention Type
Device
Intervention Name(s)
High Intensity Focused Ultrasound
Other Intervention Name(s)
TH-One HIFU device
Intervention Description
One or two HIFU sessions
Primary Outcome Measure Information:
Title
Eucalcaemia
Description
Calcium in the blood is measured from venepuncture
Time Frame
12 months post-treatment
Secondary Outcome Measure Information:
Title
Eucalcaemia
Description
Ca in plasma
Time Frame
Six weeks post-treatment.Six month data were also intended to be reported, however, six month data were not analyzed because only one subject was entered and this subject was withdrawn from the study before six months after treatment.
Title
Voice Morbidity
Description
Voice Handicap Index. 30 questions rated on a five point scale from 'never' to 'always' and an overall score from 1 'normal' to 10 'severely impaired'
Time Frame
Up to one year post-treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Primary Hyperparathyroidism (PHPT) Moderate/severe hypercalcaemia (Ca>2.8mmol/L) Positive sestamibi scan demonstrating a cervical parathyroid adenoma Adenoma visible on ultrasound scan Exclusion Criteria: Large adenoma (>15mm) Deep adenoma (>20mm from skin surface Familial disease (eg members of MEN-1 families) Inability to complete questionnaires in English without making mistakes or needing help with translation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Radu Mihai
Organizational Affiliation
Oxford University Hospitals NHS Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
John Radcliffe Hospital
City
Oxford
ZIP/Postal Code
OX3 9DU
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma

We'll reach out to this number within 24 hrs